When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TAK - A Look At The Competitors To Minerva's Roluperidone
Takeda Pharmaceutical Company Limited American Depositary Shares
Minerva Neurosciences (NERV) is set to report data from multiple clinical trials in 2019 but roluperidone, which NERV is developing as a treatment for the negative symptoms of schizophrenia, is likely to get a disproportionate amount of attention. NERV and others developing in the negative symptoms space are quick to note that there is no FDA approved therapy specifically for the negative symptoms of schizophrenia. Despite that, if successful, roluperidone could still face some competition from off-label use of existing antipsychotics and eventually new antipsychotics which are also currently in development. This article